Ocular Hypertension News

FDA Committee Backs Netarsudil, a Once-Daily Glaucoma Drug - Medscape



Medscape
 
FDA Committee Backs Netarsudil, a Once-Daily Glaucoma Drug 
Medscape
A first-in-its-class eye drop to reduce intraocular pressure (IOP) for patients with open-angle glaucoma or ocular hypertension drew high marks at an FDA advisory committee meeting on October 13. Aerie Pharmaceuticals representatives discussed ...
FDA committee gives push forward for Aerie's Rhopressa Healio
FDA Advisory Committee Gives Nod to Rhopressa MD Magazine
Aerie Pharmaceuticals Announces FDA Advisory Committee Vote in Favor of Rhopressa? (netarsudil ophthalmic ... Business Wire (press release)
Nasdaq  -Triangle Business Journal  -Zacks Investment Research 
all 103 news articles » 


$1.35 EPS Expected for Magna International Inc. (USA) (MGA ... - UtahHerald.com



UtahHerald.com
 
$1.35 EPS Expected for Magna International Inc. (USA) (MGA ... 
UtahHerald.com
Analysts expect Magna International Inc. (USA) (NYSE:MGA) to report $1.35 EPS on November, 2.They anticipate $0.06 EPS change or 4.65% from last ...
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Short Interest Down by ... HugoPress
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Short Interest decreased ... Finance Daily

all 7 news articles » 


Aerie (AERI) Up on FDA Review Committee Result for Rhopressa - Nasdaq



Aerie (AERI) Up on FDA Review Committee Result for Rhopressa 
Nasdaq
Roclatan is a once-daily, quadruple-action fixed-dose combination of Rhopressa and Pfizer's PFE Xalatan, is being evaluated to lower IOP in patients with glaucoma or ocular hypertension. The company plans to submit its NDA for the same in the first ...

and more » 


FDA panel backs approval of Aerie's Rhopressa for glaucoma treatment - Pharmaceutical Business Review



FDA panel backs approval of Aerie's Rhopressa for glaucoma treatment 
Pharmaceutical Business Review
Aerie Pharmaceuticals' Rhopressa (netarsudil ophthalmic solution) 0.02% has been recommended for approval by an advisory panel of the US Food and Drug Administration (FDA) for the treatment of glaucoma and ocular hypertension. All the ten members ...

 


Ocular Therapeutix (OCUL) Reaches $5.78 After 9.00% Up Move; Zebra Technologies (ZBRA)'s Sentiment Is 1.12 - UtahHerald.com



Ocular Therapeutix (OCUL) Reaches $5.78 After 9.00% Up Move; Zebra Technologies (ZBRA)'s Sentiment Is 1.12 
UtahHerald.com
It currently has negative earnings. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Analysts await Ocular Therapeutix Inc (NASDAQ:OCUL) to report earnings on November, 8. They expect $-0.56 earnings ...
Financial Comparison: Transenterix (TRXC) & Ocular Therapeutix (OCUL) Dispatch Tribunal
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Trading Volume Significantly Lower Modern Readers

all 15 news articles » 


The FDA's insider view on Aerie's glaucoma drug: Yes on efficacy, but? - Endpoints News



BZ Weekly
 
The FDA's insider view on Aerie's glaucoma drug: Yes on efficacy, but? 
Endpoints News
The current proposed label reads as follows, ?RHOPRESSA (netarsudil ophthalmic solution) 0.02% is a Rho kinase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.? We ...
Aerie climbs after FDA briefing concurs with efficacy claims FierceBiotech
Aerie Pharma's FDA Briefing Docs: Good News With No Surprises; Shares Scale A Record Benzinga
Aerie Pharmaceuticals Inc's (AERI) Glaucoma Drug Is Poised for a Favorable AdCom: Cantor Smarter Analyst
HugoPress  -Zacks Investment Research  -SEC.gov  -SEC.gov 
all 132 news articles » 


pSivida and Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular ... - GlobeNewswire (press release)



HuronReport
 
pSivida and Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular ... 
GlobeNewswire (press release)
... of combining pSivida's bioerodible sustained release drug delivery system with Nicox's nitric oxide (NO)-donating compounds, to develop a sustained release drug to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension ...
pSivida (PSDV) Stock: Gains On Collaboration Agreement CNA Finance (press release)

all 45 news articles » 


Analyzing Transenterix (TRXC) & Ocular Therapeutix (OCUL) - StockNewsTimes



BZ Weekly
 
Analyzing Transenterix (TRXC) & Ocular Therapeutix (OCUL) 
StockNewsTimes
Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are ...
EPS for Ocular Therapeutix Inc (OCUL) Expected At $-0.56 BZ Weekly
Ocular Therapeutix, Inc. (OCUL) Valuation According To Analysts UK Market News

all 14 news articles » 


AERI Faces D-Day, PTI To Report Data In Q4, MACK Makes Peace, MNKD Pulls Back - Nasdaq



AERI Faces D-Day, PTI To Report Data In Q4, MACK Makes Peace, MNKD Pulls Back 
Nasdaq
The Company is seeking approval of Rhopressa for the treatment of patients with open-angle glaucoma or ocular hypertension. Open-angle glaucoma, which is the most common form of glaucoma, is caused by the slow clogging of trabecular meshwork - the ...

and more » 


Today's optometrist must look beyond the eye - Healio



Today's optometrist must look beyond the eye 
Healio
First, patients, to a large degree, still don't see the link between ocular and systemic health. Many view us as their guardian of vision and not as someone who evaluates overall health. Second, there is a lot of undetected hypertension out there ...